Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis.
In a double-blind study, diphenylpyraline (Lergobine) was given to 63 patients whose main symptoms were stuffiness of the nose, increased secretion of mucus, snuffling, sneezing and redness of the eyes. Fifty-seven patients were given placebo for identical symptoms. Diphenylpyraline was found to have a better effect on all the symptoms than placebo. The difference was statistically significant in respect of the discharge of mucus and redness of the eyes, and when the total symptoms were considered as a whole. In atopic patients the better effect of diphenylpyraline was highly significant.
D000293:Adolescent; D000328:Adult; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012882:Skin Tests
D001559:Benzhydryl Compounds; D003692:Delayed-Action Preparations; D006634:Histamine H1 Antagonists; D010880:Piperidines; D010919:Placebos; C009871:diphenylpyraline